Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Common Equity (2018 - 2026)

Immunovant filings provide 8 years of Common Equity readings, the most recent being $986.1 million for Q4 2025.

  • Quarterly Common Equity rose 179.66% to $986.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $986.1 million through Dec 2025, up 179.66% year-over-year, with the annual reading at $707.4 million for FY2025, 14.52% up from the prior year.
  • Common Equity hit $986.1 million in Q4 2025 for Immunovant, up from $519.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $986.1 million in Q4 2025 and bottomed at $251.8 million in Q3 2023.
  • Average Common Equity over 5 years is $494.7 million, with a median of $459.4 million recorded in 2022.
  • The largest annual shift saw Common Equity soared 316.16% in 2021 before it tumbled 48.09% in 2024.
  • Immunovant's Common Equity stood at $505.1 million in 2021, then decreased by 17.91% to $414.7 million in 2022, then soared by 63.82% to $679.3 million in 2023, then tumbled by 48.09% to $352.6 million in 2024, then soared by 179.66% to $986.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Common Equity are $986.1 million (Q4 2025), $519.7 million (Q3 2025), and $608.5 million (Q2 2025).